Popular Stories
RADAR on Medicare Advantage
-
In its final annual update to the Medicare Advantage and Part D programs, President Joe Biden’s CMS on Nov. 26 issued a proposed rule that contained a slew of marketing and communications provisions slated to...
-
Acknowledging the growing prevalence of obesity in the U.S. and its existence as a chronic disease, CMS in its proposed Medicare Advantage and Part D rule for the 2026 contract year included a landmark provision...
HEALTH PLAN WEEKLY
-
Humana Inc. on Dec. 3 announced the hiring of a new chief financial officer, Celeste Mellet, who will replace Susan Diamond after she steps down on Jan. 11 after more than three years as CFO. While Mellet...
-
Policy changes — particularly those aimed at eliminating hospital facility fees — are top of mind for stakeholders and health benefits purchasers eager to stem the tide of rising health care costs...
Radar On Speciality Pharmacy
-
Almost one year after the FDA put its approval decision on hold, Lilly has finally crossed the finish line with Ebglyss (lebrikizumab-lbkz). The approval means another option for the treatment of atopic dermatitis...
-
How the FDA fares during President-elect Donald Trump’s second term will depend, in part, on the pharmaceutical industry’s support for the agency and its staff, Commissioner Robert Califf told the Friends of...
RADAR ON DRUG BENEFITS
-
Small-molecule drugs and biologics may produce similar health benefits, but because small molecules tend to be priced lower than biologics, they often represent better value, according to a recent...
-
Employer plan sponsors in recent years have struggled to contain the costs associated with the increasing demand from beneficiaries to use GLP-1 medications for obesity and diabetes. For instance, Aon,...
About AIS Health
AIS Health is a publishing and information company that has served the health care industry for more than 30 years. Our mission is to provide our readers with an actionable understanding of the business of health care and pharmaceuticals. Our in-depth writing covers the companies, people, catalysts and trends that create the richly textured contours of the health care and drug industry. AIS Health maintains journalistic independence from our parent company, MMIT. We are committed to integrity in reporting and bringing transparency to health industry data.
The Latest
Complimentary Publications
Premium Categories
Premium Categories
Get an actionable understanding of the business of health care and pharmaceuticals
Sign up for publications to get unmatched business intelligence delivered to your inbox.